Phase I Study of a Plasmid DNA Vaccine Encoding MART-1 in Patients with Resected Melanoma at Risk for Relapse

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of immunotherapy

• Publication date

  2005-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.cji.0000162779.88687.4cPMID 16000957
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduced immunogenicity of DNA vaccine plasmids in mixtures

  2004cited by this paper
• Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma

  2004cited by this paper
• Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance.

  2004cited by this paper
• Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination.

  2003cited by this paper
• Induction of immune responses by DNA vaccines in large animals.

  2003cited by this paper
• Inability to Immunize Patients with Metastatic Melanoma Using Plasmid DNA Encoding the gp100 Melanoma-Melanocyte Antigen

  2003cited by this paper
• A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.

  2003cited by this paper
• Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma

  2003cited by this paper
• Gene Vaccines

  2003cited by this paper
• Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.

  2002cited by this paper
• Clinical cancer vaccine trials.

  2002cited by this paper
• In vivo activation of melanoma‐specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus‐specific T cells

  2002cited by this paper
• Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.

  2002cited by this paper
• The Potential of DNA Vaccination against Tumor-Associated Antigens for Antitumor Therapy

  2002cited by this paper
• Melanoma Vaccines

  2002cited by this paper
• Prophylactic Tumor Vaccination: Comparison of Effector Mechanisms Initiated by Protein Versus DNA Vaccination1

  2001cited by this paper
• Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12.

  2001cited by this paper
• Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.

  2001cited by this paper
• Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model

  2001cited by this paper
• Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene

  2001cited by this paper
• Detection and quantification of CD8(+) T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-gamma-ELISPOT assay.

  2001cited by this paper
• Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition

  2001cited by this paper
• Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial Antigens

  2001cited by this paper
• Development of a Polynucleotide Vaccine from Melanoma Antigen Recognized by T Cells-1 and Recombinant Protein from Melanoma Antigen Recognized by T Cells-1 for Melanoma Vaccine Clinical Trials

  2000influential reference
• Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers.

  2000cited by this paper
• Cationic microparticles: A potent delivery system for DNA vaccines.

  2000cited by this paper
• Increased DNA Vaccine Delivery and Immunogenicity by Electroporation In Vivo

  2000cited by this paper
• Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines.

  2000cited by this paper
• Phase I study in melanoma patients of a vaccine with peptide‐pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells

  2000cited by this paper
• Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine.

  2000cited by this paper
• Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin.

  1999cited by this paper
• Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device.

  1999cited by this paper
• Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

  1998cited by this paper
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  1998cited by this paper
• Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients.

  1998cited by this paper
• Cytokines and costimulatory molecules as genetic adjuvants

  1997cited by this paper
• Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors.

  1997cited by this paper
• Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

  1997cited by this paper
• Gene vaccines.

  1996cited by this paper
• Generation of cytotoxic T‐cell responses with synthetic melanoma‐associated peptides in vivo: Implications for tumor vaccines with melanoma‐associated antigens

  1996cited by this paper
• Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization

  1996cited by this paper
• Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.

  1996cited by this paper
• Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen.

  1996cited by this paper
• A carcinoembryonic antigen polynucleotide vaccine for human clinical use.

  1995cited by this paper
• Immunization by Direct DNA Inoculation Induces Rejection of Tumor Cell Challenge

  1995cited by this paper
• A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity.

  1995cited by this paper
• Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells.

  1991cited by this paper
• The distribution of iron and iron binding proteins in spleen with reference to Hodgkin's disease.

  1986cited by this paper

• Intradermal Naked DNA Vaccination by DNA Tattooing for Mounting Tumor-Specific Immunity in Stage IV Melanoma Patients: A Phase I Clinical Trial

  2024influential citation
• Non-viral Vector for Muscle-Mediated Gene Therapy

  2018cites this paper
• DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.

  2016cites this paper
• Preclinical and clinical development of DNA vaccines for prostate cancer.

  2016cites this paper
• Generation of Large Numbers of Antigen-Expressing Human Dendritic Cells Using CD14-ML Technology

  2016cites this paper
• Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.

  2015cites this paper
• Immunology of Cutaneous Tumors and Immunotherapy for Melanoma

  2015cites this paper
• Melanoma versus vitiligo: Clinical aspects and implications for immunotherapy

  2015cites this paper
• CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA

  2014cites this paper
• Trial watch

  2013cites this paper
• Trial Watch

  2013cites this paper
• Characterisation of high and low avidity peptide specific CD8+ T cells using immunologic, transcriptomic and proteomic tools

  2013cites this paper
• HUMAN ENDOGENOUS RETROVIRUS K AS A NOVEL TUMOR-ASSOCIATED ANTIGEN FOR DEVELOPMENT OF AN OVARIAN CANCER VACCINE

  2012cites this paper
• Immunotherapy of cancer in 2012

  2012cites this paper
• New cloning and expression vector derived from Escherichia coli plasmid pIGWZ12; a potential vector for a two-plasmid expression system.

  2012cites this paper
• Suppression of murine melanoma growth by a vaccine of attenuated Salmonella carrying heat shock protein 70 and Herpes simplex virus-thymidine kinase genes.

  2011cites this paper
• DNA vaccination in oncology: current status, opportunities and perspectives.

  2010cites this paper
• Herpes simplex virus oncolytic vaccine therapy in melanoma

  2010influential citation
• TAA Polyepitope DNA-Based Vaccines: A Potential Tool for Cancer Therapy

  2010cites this paper
• DNA Vaccination: Using the Patient's Immune System to Overcome Cancer

  2010cites this paper
• Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine

  2010cites this paper
• Poly-N-acetyl glucosamine gel matrix as a non-viral delivery vector for DNA-based vaccination.

  2010cites this paper
• Pharmaceutical development of the plasmid DNA vaccine pDERMATT

  2009cites this paper
• Formulation and delivery of dermal DNA vaccines

  2009cites this paper
• Methods for constructing and evaluating antitumor DNA vaccines.

  2009cites this paper
• Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects

  2009cites this paper
• PMMA particle-mediated DNA vaccine for cervical cancer.

  2009cites this paper
• Toxicology and biodistribution study of CIGB-230, a DNA vaccine against hepatitis C virus

  2009cites this paper
• Muscular gene transfer using nonviral vectors.

  2008cites this paper
• Phase 1 Trial of Intranodal Injection of a Melan-A/MART-1 DNA Plasmid Vaccine in Patients With Stage IV Melanoma

  2008cites this paper
• Plasmid DNA- and messenger RNA-based anti-cancer vaccination.

  2008cites this paper
• Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses.

  2008cites this paper
• GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial.

  2008cites this paper
• Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial.

  2008cites this paper
• DNA vaccines: precision tools for activating effective immunity against cancer

  2008cites this paper
• Vaccines as Targeted Cancer Therapy

  2008cites this paper
• HLA typing demands for peptide-based anti-cancer vaccine

  2008cites this paper
• Immunotherapy of melanoma: a critical review of current concepts and future strategies

  2007cites this paper
• Plasmid DNA and viral vector-based vaccines for the treatment of cancer.

  2007cites this paper
• Novel experimental therapies for atherosclerosis : a genomics based approach

  2007cites this paper
• General Principles of Tumor Immunotherapy

  2007cites this paper
• Next generation: tuberculosis vaccines that elicit protective CD8+ T cells

  2007cites this paper
• Towards progress on DNA vaccines for cancer

  2007cites this paper
• Effect of Plasmid DNA Vaccine Design and In Vivo Electroporation on the Resulting Vaccine-Specific Immune Responses in Rhesus Macaques

  2007cites this paper
• Investigating the potential of the Metastasis Associated Antigen 1 (MTA1) for cancer immunotherapy in a murine model

  2007cites this paper
• Current immunotherapeutic strategies in malignant melanoma.

  2007cites this paper
• DNA vaccines against cancer.

  2006influential citation
• Specific active immunotherapy of cancer: potential and perspectives.

  2006cites this paper
• Vaccination with liposome–DNA complexes elicits enhanced antitumor immunity

  2006cites this paper
• Gene-based vaccines: recent technical and clinical advances.

  2006cites this paper
• DNA vaccines: Successes and limitations in cancer and infectious disease

  2006cites this paper